Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-830-3 | CAS number: 7758-02-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1988
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: EPA FIFRA 81-1
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Sodium bromide
- EC Number:
- 231-599-9
- EC Name:
- Sodium bromide
- Cas Number:
- 7647-15-6
- IUPAC Name:
- sodium bromide
- Details on test material:
- - Name of test material (as cited in study report): Active ingredient ´Sodium bromide, technical grade (99,23 %)
- Description: White powder
- Analytical purity: 99.23 %
- Lot/batch No.: Batch No.: 7320
- Stability under test conditions: not determined
Potassium bromide is an inorganic salt that dissociates to its composite ions in aqueous solutions at environmental pH and temperature. Comparison of the available data on the various bromide salts have shown that the bromide ion is the relevant ion for determination of the toxicological profile with simple cations such as potassium, sodium or ammonium, that are ubiquitous in nature, having little or no influence on the bromide ion properties. It is therefore justified to read-across data from other inorganic bromide salts to potassium bromide.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD [Crl: CD(SD)BR]
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River U. K. Limited, Margate, Kent, England
- Age at study initiation: six weeks
- Weight at study initiation: 112 to 150 g
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1 % aqueous methylcellulose
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: Sodium bromide was prepared at various concentrations in 1% aqueous methylcellulose and administered at a volume of 20 ml/kg.
- Amount of vehicle (if gavage): 20 ml/kg bodyweight
MAXIMUM DOSE VOLUME APPLIED: 20 ml/kg bodyweight
- Doses:
- Preliminary study: 2 g/kg bw and 5 g/kg bw
Main Study: 3.2 g/kg bw, 4 g/kg bw and 5 g/kg bw - No. of animals per sex per dose:
- 5/sex/group
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for clinical signs and mortality soon after dosing and at frequent intervals for the remainder of day 1. On subsequent days the animals were observed twice daily for 5 (preliminary study) and 14 days (main study) respectively.
Individual bodyweights of rats were taken on Days 1 (day of dosing), 8 and 15 and at death.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight; A pre-test was carried out to establish a dosing regimen using groups of two male and two female rats at two dose levels of 2 and 5 g/kg bodyweight. Animals were observed for mortality and clinical signs for 5 days.
Results and discussion
- Preliminary study:
- The results indicated that the acute median lethal oral dose of sodium bromide, technical grade, was greater than 5 g/kg bodyweight for male rats and between 2 and 5 g/kg bodyweight for female rats.
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 4.2 other: g/kg bw
- Mortality:
- Two female rats dosed at 5 g/kg bodyweight died on Day 4 of preliminary study. All other animals survived during the study period of five days.
During the main study there were deaths amongst rats of both sexes dosed at 4 and 5 g/kg. Deaths occurred from Day 3 to Day 7. One male was sacrificed after being found moribund on Day 5. - Clinical signs:
- Signs of reaction to treatment observed were recorded for animals in the main study only. All treated animals showed piloerection within 5 minutes of dosing and abnormal body carriage (hunched posture), abnormal gate (waddling), lethargy, decreased respiratory gate, ptosis and pallor of the extremities within three hours of dosing. Other reactions first observed at, or later than three hours were: ataxia (all rats dosed 4 g/kg and above) and prostration (one female rat dosed 3.2 g/kg, most rats dosed at 4 g/kg and all rats dosed at 5 g/kg)
- Body weight:
- Low bodyweight gains, and in one case a bodyweight loss, were recorded on day 8 for rats at all dose levels. Anticipated bodyweight gains were achieved during the second week of the study. Body weight losses were recorded for all rats that died
- Gross pathology:
- Autopsy of rats that died commonly revealed slight congestion of the glandular region of the stomach; red coloured fluid was observed in the urinary bladder of a single male (4 g/kg); isolated cases of congestion or vascular congestion of other zones of the gastrointestinal tract.
Terminal autopsy findings of rats killed at the end of the study, were normal.
Any other information on results incl. tables
Table A6.1.1/02-1 Summary of Acute Oral Toxicity |
|||||
Dose g/kg |
Number of dead / |
Time of death (range) |
Observations |
||
male |
female |
||||
3.2 |
0/5 |
0/5 |
- |
Piloerection, hunched posture, waddling, lethargy, decreased respiratory rate, ptosis, pallor of extremities, prostrate |
|
4 |
1/5 |
3/5 |
Day 5-7 |
Piloerection, hunched posture, waddling, lethargy, decreased respiratory rate, ptosis, pallor of extremities, ataxia, prostrate |
|
5 |
4/5 |
5/5 |
Day 3-6 |
Piloerection, hunched posture, waddling, lethargy, decreased respiratory rate, ptosis, pallor of extremities, ataxia, prostrate, moribund (apathy, prostrate, cyanosis, decreased respiration) |
|
LD50 value |
4.5 g/kg bw (males), 3.9 g/kg bw (females), 4.2 g/kg bw (combined) |
|
|||
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 was determined to be 4.5 g/kg bw (males), 3.9 g/kg bw (females) and 4.2 g/kg bw (both sexes combined). In accordance with CLP Regulation (EC) No 1272/2008, sodium bromide does not have to be classified and labelled with respect to acute oral toxicity.
- Executive summary:
Materials and methods
The study was designed to assess the toxicity following a single oral dose of sodium bromide. Groups of 5 fasted CD rats received a single oral dose of the test substance formulated in 1 % aqueous methylcellulose and administered at a volume of 20 ml/kg and dose levels of 3.2; 4 and 5 g/kg bw. Animals were observed for mortality and clinical signs soon after dosing, at frequent intervals for the remainder of day 1 and twice daily on the subsequent days. Body weights were taken on Day 1, 8 and 15 and at death. All animals were subject to necropsy and LD50 was determined.
Results and discussion
Signs of reaction observed were piloerection, abnormal body carriage, abnormal gait, lethargy, decreased respiratory rate, ptosis, pallor of the extremities, ataxia and prostration. There were death amongst rats of both sexes dosed at 4 and 5 g/kg. Autopsy of these rats revealed slight congestion of the glandular region of the stomach; red coloured fluid was observed in the urinary bladder of a single male (4 g/kg) and isolated cases of congestion or vascular congestion of other zones of the gastrointestinal tract were observed. Low bodyweight gains were recorded for surviving rats at all dose levels. Body weight losses were recorded for all rats that died.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
